The rise in malaria prevalence in developing countries is a major factor driving the growth of the anti-malarial drugs market. Furthermore, increased government awareness initiatives and increased research for new antimalarial drugs are some of the factors driving the market growth.
To avoid an increase in the number of patients and to reduce the risk of traveler's malaria, regulatory authorities advise travelers to bring antimalarial medications with them. The others segment accounted for the lion's share of the anti-malarial drugs market. Furthermore, the segment is expected to grow at the fastest rate during the forecast period, owing to the fact that malaria parasites have successfully developed resistance to the majority of the drugs currently on the market.
New drugs, particularly those with novel mechanisms of action, are required. The history of anti-malarial medicines is reviewed here, beginning with the discovery of quinine in the early 1800s and progressing to modern-day ACT and the recently-approved tafenoquine. A number of new potential anti-malarial drugs currently in development are described, as well as the hit-to-lead campaign that inspired them. Finally, promising novel mechanisms of action for these and future anti-malarial drugs are described.
Read more @ https://bit.ly/3F18LlH
